Breaking News
March 18, 2019 - Fibromyalgia can be reliably detected in blood samples
March 18, 2019 - Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmaceutical Ingredient (API)
March 18, 2019 - Researchers identify early home and family factors that contribute to obesity
March 18, 2019 - Fate and festivity: Match Day 2019
March 18, 2019 - Study finds TAVR to be as good as open-heart surgery for patients at low surgical risk
March 18, 2019 - EU-funded project is developing new tools for diagnosing cancer
March 18, 2019 - Gluten, lactose, food dyes in pills could be causing side effects finds study
March 18, 2019 - Taking painkillers during pregnancy is not responsible for asthma risk in children, study shows
March 18, 2019 - Prediagnosis Psychiatric Care Linked to Worse Cancer Mortality
March 18, 2019 - Paris hospital halts stool study after donor deluge
March 18, 2019 - Partial oral antibiotic therapy shows efficacy and safety in patients with infectious endocarditis
March 18, 2019 - Olympus improves access to science education through BioBus collaboration
March 18, 2019 - Depression screening does not improve quality of life in heart attack patients
March 18, 2019 - Echocardiography may aid in patient selection for TMVR
March 18, 2019 - Are ‘Inactive’ Ingredients in Your Drugs Really So Harmless?
March 18, 2019 - Wearable technology can safely identify atrial fibrillation
March 18, 2019 - Scientists tackle rare retinal disease in unique research project
March 18, 2019 - Death By A Thousand Clicks
March 18, 2019 - Absorbable, antibiotic-eluting envelope can reduce rate of cardiac device infections
March 18, 2019 - Hormonal treatment associated with depression in men with prostate cancer
March 18, 2019 - Porvair Sciences launches reinforced 96-well deep round microplate
March 18, 2019 - Simplified catheter ablation could slash waiting lists for atrial fibrillation patients
March 18, 2019 - BFR therapy as part of rehabilitation following ACL surgery may slow bone loss
March 18, 2019 - A human model to test implants for cataract surgery
March 18, 2019 - New risk adjustment model could reduce financial penalty for safety net hospitals
March 18, 2019 - NHS cancer patients’ wait to start treatment worrying
March 18, 2019 - Inventiva Announces Results from Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
March 18, 2019 - Cologuard
March 18, 2019 - Researchers find evidence of prenatal environment tuning genomic imprinting
March 18, 2019 - Dolomite Bio launches novel Nadia product family for single-cell research
March 18, 2019 - Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
March 18, 2019 - Excessive gestational weight gain tied to maternal morbidity
March 18, 2019 - RCEM issues position statement on metrics to supplement four-hour standard target
March 17, 2019 - Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
March 17, 2019 - Brain region plays key role in regulation of parenting behavior, study finds
March 17, 2019 - Natural speed limit on DNA replication sets pace for life’s first steps
March 17, 2019 - New research reveals overlooked impact of herbicide glyphosate on the environment
March 17, 2019 - Molecular patterns could help predict relapse risk in breast cancer patients
March 17, 2019 - Study confirms sensitivity of microbiological cultures for detecting cholera
March 17, 2019 - Scientists Spot Clues to Predicting Breast Cancer’s Return
March 17, 2019 - Scientists identify gene that keeps PTSD-like behavior at bay in female mice
March 17, 2019 - New method would allow doctors to detect earliest stages of cancers in the lymph nodes
March 17, 2019 - Cholesterol protein discovery raises hope for smarter drugs
March 17, 2019 - New insect medium delivers high viable cell density growth and protein yield
March 17, 2019 - Opioid crisis brings concerns about heart dangers
March 17, 2019 - Resistance Training May Prevent Type 2 Diabetes Progression
March 17, 2019 - Bioluminescence sensors make new approaches to drug discovery possible
March 17, 2019 - New FDA Rules Aim to Keep Kids From Flavored E-Cigarettes
March 17, 2019 - Vitamin B3 analogue boosts production of blood cells
March 17, 2019 - Government cuts to stop smoking services have detrimental impact on public health
March 17, 2019 - Common tool to assess potential adoptive parents lags behind societal changes
March 17, 2019 - Patients’ own cells could be the key to treating Crohn’s disease
March 17, 2019 - Diagnostic delays common in inflammatory bowel disease
March 17, 2019 - Study uncovers dramatic differences in the brains of Hispanics with dementia
March 17, 2019 - Study describes epigenetic loss that changes how cells obtain energy from cancer
March 16, 2019 - Active Bathing in Non-ICU Setting Does Not Cut Infections
March 16, 2019 - How the immune system maintains a healthy gut microbiota
March 16, 2019 - Bacteria ‘trap’ could help in the fight against antimicrobial resistance
March 16, 2019 - Hospital work environment associated with all EHR usability outcomes
March 16, 2019 - Study unravels mystery behind how the brain encodes time when forming long-term memories
March 16, 2019 - Light physical activity may lower risk of cardiovascular disease in older women
March 16, 2019 - USP15 enzyme could potentially lead to new treatments for breast, pancreatic cancer
March 16, 2019 - After Chinese Infant Gene-Editing Scandal, U.S. Health Officials Join Call for a Ban
March 16, 2019 - PACS1 syndrome – Genetics Home Reference
March 16, 2019 - Researchers discover an unexpected organization of antimicrobial molecules that amplifies immune response
March 16, 2019 - With New Study, Era of Open-Heart Surgery for Aortic Stenosis May be Ending
March 16, 2019 - Dolomite Bio introduces high throughput sNuc-Seq protocol for its Nadia Instrument
March 16, 2019 - New course prepares materials scientists for biomedical testing
March 16, 2019 - Finding clues to a functional HIV cure
March 16, 2019 - People with chronic periodontitis have higher risk for dementia
March 16, 2019 - Few heart care recommendations are based on rigorous study
March 16, 2019 - Colorectal cancer diagnosed at early age is distinct from that in older patients
March 16, 2019 - Researchers use MRI and AI techniques at birth to predict cognitive development at age 2
March 16, 2019 - Discarding information from the brain linked to more mental effort, finds study
March 16, 2019 - OTA International supplement provides current snapshot and forward look at global trauma systems
March 16, 2019 - NIH trial to track outcomes of liver transplantation from HIV+ donors to HIV+ recipients
March 16, 2019 - Apple Heart Study shows how wearable technology can help detect heart problem
March 16, 2019 - Researchers determine factors that cause stress development in the human body
March 16, 2019 - Elderly Men Undertreated for Osteoporosis
March 16, 2019 - People with chronic pain are coping with the help of Pinterest, new study reveals
Study uncovers mechanism causing chronic GVHD after bone marrow transplant

Study uncovers mechanism causing chronic GVHD after bone marrow transplant

image_pdfDownload PDFimage_print

Allogeneic bone marrow transplant (BMT) is an essential treatment to cure patients with blood cancers such as leukemia. In patients who have undergone chemotherapy and radiation, a small number of cancer cells can remain in the bloodstream and allow the malignancy to recur.

Replacing host bone marrow is the best strategy for preventing relapse but recipients cannot always find an ideal, biologically matched donor. The less well-matched the donor, the higher the risk for developing graft-versus-host disease (GVHD). In GVHD, donor cells trigger an immune response that attacks normal tissues, leading to a chain reaction of cellular and molecular responses that increase morbidity and mortality in these patients. A long-standing question has been how to improve the success of BMT by reducing GVHD incidence while, at the same time, preserving the anti-tumor response of donor cells.

New research by a team of investigators at the Medical University of South Carolina (MUSC) directed by Xue-Zhong Yu, M.D., professor of Microbiology and Immunology, in collaboration with researchers at the University of Minnesota, demonstrates that one particular family of microRNAs (miRs), called miR-17-92, is responsible for the T-cell and B-cell pathogenicity that causes GVHD. The findings were reported in an article prepublished online on March 12, 2018 by Blood.

GVHD can be divided into acute (aGVDH) or chronic forms (cGVHD). “They are very different diseases,” explains Yongxia Wu, Ph.D., a postdoctoral fellow and lead author on the article. “Our ability to prevent or treat aGVHD has considerably improved, but the incidence of cGVHD continues to increase. Chronic GVHD has a different pathophysiology and different target organs than aGVHD. It’s been a big challenge to try to find a target for cGVHD therapies, because of the more complex immune reaction in cGVHD and the fact that its cellular and molecular mechanisms are not as well understood.”

Chronic GVHD is characterized by autoimmune-like, fibrotic changes in multiple organs such as the skin (causing scleroderma) and the lungs (causing bronchiolitis obliterans), and fibrosis of the salivary glands, liver, and gut. With 30 to 70 percent of patients who receive allogeneic BMT developing cGVHD, the lack of effective therapies is a major unmet clinical need.

The MUSC team previously found that, in aGVHD, miR-17-92 played a critical role in regulating CD4 T-cell proliferation and Th1 and Treg differentiation. Based on this work, they decided to investigate whether miR-17-92 regulates T- and B-cell differentiation and function in the development of cGVHD.

“We decided to extend our aGVHD study to cGVHD. But there’s no single, well-defined murine model that can reflect all of the clinical manifestations seen in cGVHD patients,” explains Wu. “Different patients experience different symptoms because cGVHD can be manifested in many organs — some patients have skin symptoms, some have lung symptoms — it varies. So, we decided to study four different cGVHD models to best understand how miR-17-92 contributes overall, across many clinical presentations.”

The team undertook a series of experiments to define the role of miR-17-92 in regulating T- and B-cell pathogenicity using murine models of allogeneic BMT, including models of scleroderma that had transitioned from aGVHD to cGVHD, classic cGVHD scleroderma, lung inflammation and a lupus-like condition. The team also conducted two clinical translation studies to test whether pharmacologically blocking miR-17-92 might have clinical relevance in the lupus-like condition and the scleroderma cGVHD model.

Their results demonstrated shared mechanisms by which miR-17-92 mediates cGVHD progression — namely by regulating T helper-cell differentiation, B-cell activation, germinal center responses, and autoantibody production. The clinical translation studies also found that miR-17 blockade alleviated proteinuria (in the lupus-like condition) and scleroderma symptoms.

“The mechanism for how miR-17-92 regulates T- and B-cells was very consistent. In other words, we did not find any big differences among the models,” says Wu. “So, we not only found a new mechanism for cGVHD development by demonstrating that this miR-17-92 is heavily involved in the T- and B-cell responses that lead to cGVHD, but we also found that blocking miR-17 substantially reduced cGVHD symptoms in mice. That’s exciting because it provides strong evidence that this miR may be a good target for controlling cGVHD after allogeneic BMT.”

Although miR-17-92 has been well studied, its role in cGVHD development has never before been defined. Because cGVHD has a similar pathophysiology to some autoimmune diseases, it is likely that these findings will be useful for developing new treatments and preventive therapies in other conditions.

“We are very excited to publish this work because we are hoping that a clinical research group will be inspired to take our study findings further in patients,” says Wu.

In the meantime, the MUSC team, led by Yu, will continue their work and try to extend the current findings by investigating how other miRs may be involved in regulating T- and B-cell function during allogeneic BMT.​​

Tagged with:

About author

Related Articles